- Skip Navigation

Note: This message is displayed if (1) your browser is not standards-compliant or (2) you have you disabled CSS. Read our Policies for more information.

Indiana General Assembly
House Bill 2026


Search all legislative material from the 2001 Session.
General Assembly Home Page

Session Information

Complete Bill Listing

Get Acrobat Reader
You will need to download and install Acrobat Reader to view PDF documents.


House Bill 2026

ARCHIVE (2001)

Latest Information

DIGEST OF HB 2026 (Updated March 5, 2001 5:35 PM - DI 104)

Fair pricing for prescription drugs. Establishes the Rx program to provide discounted prescription drug prices to uninsured residents of Indiana. Requires the state department of health to submit an annual report to the legislative council on the enrollment and financial status of the Rx program before January 1 of each year. Allows a drug manufacturer or labeler that sells prescription drugs in Indiana through any state funded or state operated program to enter into a rebate agreement with the department that requires rebate payments to be made to the state for the Rx program each calendar quarter. Requires the state department of health to post certain information on its website. Authorizes the state department to negotiate the amount of the rebate entered into by a manufacturer or labeler. Requires the rebate to take effect not later than January 1, 2002. Establishes a formula for the state to use in calculating discount prices for drugs covered by the rebate agreement. Requires a retail pharmacy to sell the drugs covered by the Rx program to participants in the program at the discounted price determined by the state department beginning July 1, 2002. Establishes a procedure for resolving discrepancies in rebate amounts. Allows the state department to audit a manufacturer or labeler to determine whether the price negotiated complies with certain requirements. Provides the state with remedies for a violation. Establishes the Rx dedicated fund, consisting of: (1) revenue from manufacturers and labelers who pay rebates; and (2) appropriations or allocations to the fund.
Current Status:
 Passed 2nd reading - first House
>Latest Printing > (PDF)